人福医药：控股子公司获得《药物临床试验批准通知书》

Group 1 - The core point of the article is that Renfu Pharmaceutical has received approval from the National Medical Products Administration for the clinical trial of Pregabalin sustained-release tablets through its subsidiary Yichang Renfu Pharmaceutical [1] - For the year 2024, Renfu Pharmaceutical's revenue composition is as follows: 56.01% from pharmaceuticals, 43.8% from pharmaceutical wholesale and related businesses, and 0.19% from other businesses [1] - As of the report, Renfu Pharmaceutical has a market capitalization of 33.8 billion yuan [1]